These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 22359620)

  • 1. Specific and sensitive hydrolysis probe-based real-time PCR detection of epidermal growth factor receptor variant III in oral squamous cell carcinoma.
    McIntyre JB; Bose P; Klimowicz AC; Brockton NT; Petrillo S; Matthews W; Easaw J; Magliocco A; Dort JC
    PLoS One; 2012; 7(2):e31723. PubMed ID: 22359620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor variant III in head and neck squamous cell carcinoma is not relevant for targeted therapy and irradiation.
    Thomas Koch D; Pickhard A; Gebel L; Buchberger AMS; Bas M; Mogler C; Reiter R; Piontek G; Wirth M
    Oncotarget; 2017 May; 8(20):32668-32682. PubMed ID: 28427242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Head and neck squamous cell carcinomas do not express EGFRvIII.
    Melchers LJ; Clausen MJ; Mastik MF; Slagter-Menkema L; Langendijk JA; van der Laan BF; van der Wal JE; van der Vegt B; Roodenburg JL; Schuuring E
    Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):454-62. PubMed ID: 25304797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges in EGFRvIII detection in head and neck squamous cell carcinoma.
    Wheeler SE; Egloff AM; Wang L; James CD; Hammerman PS; Grandis JR
    PLoS One; 2015; 10(2):e0117781. PubMed ID: 25658924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rare occurrence of EGFRvIII deletion in head and neck squamous cell carcinoma.
    Khattri A; Zuo Z; Brägelmann J; Keck MK; El Dinali M; Brown CD; Stricker T; Munagala A; Cohen EE; Lingen MW; White KP; Vokes EE; Seiwert TY
    Oral Oncol; 2015 Jan; 51(1):53-8. PubMed ID: 25255959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples.
    Yoshimoto K; Dang J; Zhu S; Nathanson D; Huang T; Dumont R; Seligson DB; Yong WH; Xiong Z; Rao N; Winther H; Chakravarti A; Bigner DD; Mellinghoff IK; Horvath S; Cavenee WK; Cloughesy TF; Mischel PS
    Clin Cancer Res; 2008 Jan; 14(2):488-93. PubMed ID: 18223223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
    Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
    Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer.
    Kim HJ; Lee KY; Kim YC; Kim KS; Lee SY; Jang TW; Lee MK; Shin KC; Lee GH; Lee JC; Lee JE; Kim SY
    Lung Cancer; 2012 Mar; 75(3):321-5. PubMed ID: 21930325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma.
    Wheeler S; Siwak DR; Chai R; LaValle C; Seethala RR; Wang L; Cieply K; Sherer C; Joy C; Mills GB; Argiris A; Siegfried JM; Grandis JR; Egloff AM
    Clin Cancer Res; 2012 Apr; 18(8):2278-89. PubMed ID: 22351687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance.
    Aldape KD; Ballman K; Furth A; Buckner JC; Giannini C; Burger PC; Scheithauer BW; Jenkins RB; James CD
    J Neuropathol Exp Neurol; 2004 Jul; 63(7):700-7. PubMed ID: 15290895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
    Chau NG; Perez-Ordonez B; Zhang K; Pham NA; Ho J; Zhang T; Ludkovski O; Wang L; Chen EX; Tsao MS; Kamel-Reid S; Siu LL
    Head Neck Oncol; 2011 Feb; 3():11. PubMed ID: 21352589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma.
    Tykocinski ES; Grant RA; Kapoor GS; Krejza J; Bohman LE; Gocke TA; Chawla S; Halpern CH; Lopinto J; Melhem ER; O'Rourke DM
    Neuro Oncol; 2012 May; 14(5):613-23. PubMed ID: 22492960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy.
    Blehm KN; Spiess PE; Bondaruk JE; Dujka ME; Villares GJ; Zhao YJ; Bogler O; Aldape KD; Grossman HB; Adam L; McConkey DJ; Czerniak BA; Dinney CP; Bar-Eli M
    Clin Cancer Res; 2006 Aug; 12(15):4671-7. PubMed ID: 16899617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous detection of EGFR amplification and EGFRvIII variant using digital PCR-based method in glioblastoma.
    Fontanilles M; Marguet F; Ruminy P; Basset C; Noel A; Beaussire L; Viennot M; Viailly PJ; Cassinari K; Chambon P; Richard D; Alexandru C; Tennevet I; Langlois O; Di Fiore F; Laquerrière A; Clatot F; Sarafan-Vasseur N
    Acta Neuropathol Commun; 2020 Apr; 8(1):52. PubMed ID: 32303258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multispectral fluorescence imaging of EGFR and PD-L1 for precision detection of oral squamous cell carcinoma: a preclinical and clinical study.
    Jin N; An Y; Tian Y; Zhang Z; He K; Chi C; Mu W; Tian J; Du Y
    BMC Med; 2024 Aug; 22(1):342. PubMed ID: 39183296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of Epidermal Growth Factor Receptor variant III in laryngeal carcinoma tissues.
    Yang B; Chen J; Zhang X; Cao J
    Auris Nasus Larynx; 2009 Dec; 36(6):682-7. PubMed ID: 19427146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens.
    Feldkamp MM; Lala P; Lau N; Roncari L; Guha A
    Neurosurgery; 1999 Dec; 45(6):1442-53. PubMed ID: 10598712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10.
    Modjtahedi H; Khelwatty SA; Kirk RS; Seddon AM; Essapen S; Del Vecchio CA; Wong AJ; Eccles S
    Br J Cancer; 2012 Feb; 106(5):883-8. PubMed ID: 22315050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates.
    Kastenhuber ER; Huse JT; Berman SH; Pedraza A; Zhang J; Suehara Y; Viale A; Cavatore M; Heguy A; Szerlip N; Ladanyi M; Brennan CW
    Acta Neuropathol; 2014 May; 127(5):747-59. PubMed ID: 24292886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.
    Learn CA; Hartzell TL; Wikstrand CJ; Archer GE; Rich JN; Friedman AH; Friedman HS; Bigner DD; Sampson JH
    Clin Cancer Res; 2004 May; 10(9):3216-24. PubMed ID: 15131063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.